Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2001 Feb 5;152(3):645–650. doi: 10.1083/jcb.152.3.645

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2001 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Inducible mouse model for EHK. (A) Bigenic +/mut^neo. CrePR1 pup after four topical applications of RU486. Scaling around the arm folds after rupture of the blister. No blisters developed in untreated bigenic +/mut^neo.CrePR1 pups or +/mut^neo or CrePR1 pups treated with RU486 (data not shown). (B) Same mouse 3 mo after induction. Note the thick brownish hyperkeratoses on the paws. (C) Light micrograph of lesional skin from B. Note the thickened stratum corneum, vacuolization, and translucency in the suprabasal layer. Hematoxylin and eosin, bar = 50 μm. (D) PCR analysis of keratinocytes captured by LCM. PCR analysis to detect the loxP site (top panel) and neo cassette (bottom panel). 1, suprabasal cells from previously treated area; 2, untreated area; 3, wild-type control mouse; 4, +/mut^loxP mouse; and 5, +/mut^neo mouse. M, DNA size marker.